Related references
Note: Only part of the references are listed.The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma
Eugene Wong et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)
Importance of GFAP isoform-specific analyses in astrocytoma
Emma J. van Bodegraven et al.
GLIA (2019)
Prognostic Implications of Extent of Resection in Glioblastoma: Analysis from a Large Database
Daniel M. Trifiletti et al.
WORLD NEUROSURGERY (2017)
Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma
Julia Tichy et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis
Hailong Zhao et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2016)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2013)
Glioblastoma: Clinical characteristics, prognostic factors and survival in 492 patients
Andreas M. Stark et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2012)
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Matthew Koshy et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Long-term survivors of glioblastoma: clinical features and molecular analysis
Yukihiko Sonoda et al.
ACTA NEUROCHIRURGICA (2009)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma
Graziella Filippini et al.
NEURO-ONCOLOGY (2008)
Serum GFAP is a diagnostic marker for glioblastoma multiforme
C. S. Jung et al.
BRAIN (2007)
Long-term survival with glioblastoma multiforme
Dietmar Krex et al.
BRAIN (2007)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression
U Wilhelmsson et al.
ONCOGENE (2003)
High expression of DNA topoisomerase IIα and Ki-67 antigen is associated with prolonged survival glioblastoma patients
M Bredel et al.
EUROPEAN JOURNAL OF CANCER (2002)
Share Paper
